Viz.ai Raises $50M in Series B round

Viz.ai’s 2019 has been marked with strong adoption of its artificial intelligence software and securing a distribution agreement with one of medtech’s biggest players. The Tel Aviv, Israel and San Francisco-based company’s latest accomplishment is raising $50 million in a series B round. The financing was led by Greenoaks with participation from Threshold Ventures, CRV along with existing investors GV and Kleiner Perkins. “This [financing] allows us to get to the next stage,” Dr. Chris Mansi, neurosurgeon, co-founder, and CEO, told MD+DI. “Our goal is to get our technology to as many patients as possible.” The company has developed a software that connects to hospital computed tomography (CT) scanners and alerts stroke specialists within minutes that a suspected LVO stroke has been identified, sending the radiological images directly to their smartphones where they can be viewed. Viz.ai enables a physician to provide the patient with the treatment they need as quickly as possible. This is important because stroke is a serious and time-sensitive medical condition that requires emergency care and can cause lasting brain damage, long-term disability, and death. Adoption rates have been significant for Viz.ai, which received a nod from FDA in February of 2018. “We’ve been on the market since June of 2018,â€...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news